The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

United Therapeutics Corp

Nasdaq: UTHR
Last

(U.S.) $169.36

Today's change+6.57 +4.04%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.
 

United Therapeutics Corp

Nasdaq: UTHR
Last

(U.S.) $169.36

Today's change+6.57 +4.04%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.

United Therapeutics Corp up sharply

United Therapeutics Corp closed up sharply Friday, rallying (U.S.)$6.57 or 4.04% to (U.S.)$169.36. Over the last five days, shares are unchanged, but have gained 30.79% over the last year to date. This security has outperformed the S&P 500 by 77.26% during the last year.

Key company metrics

  • Open(U.S.) $163.79
  • Previous close(U.S.) $162.79
  • High(U.S.) $169.71
  • Low(U.S.) $162.51
  • Bid / Ask-- / --
  • YTD % change+30.79%
  • Volume1,048,065
  • Average volume (10-day)679,220
  • Average volume (1-month)632,123
  • Average volume (3-month)620,042
  • 52-week range(U.S.) $86.04 to (U.S.) $190.29
  • Beta1.54
  • Trailing P/E53.14×
  • P/E 1 year forward24.09×
  • Forward PEG1.28×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.19
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+12.83%

Based on its net profit margin of 12.83%, United Therapeutics Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.60%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue347328346330
Total other revenue--------
Total revenue347328346330
Gross profit331307331289
Total cost of revenue16211641
Total operating expense175342168362
Selling / general / administrative11021181203
Research & development4911071119
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income172-15179-32
Interest income (expense), net non-operating-1-2-4-5
Gain (loss) on sale of assets--------
Other--------
Income before tax168-17175-36
Income after tax99-17116-25
Income tax, total69059-11
Net income99-17116-25
Total adjustments to net income--------
Net income before extra. items99-17116-25
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items99-17116-25
Inc. avail. to common incl. extra. items99-17116-25
Diluted net income99-17116-25
Dilution adjustment--------
Diluted weighted average shares52475447
Diluted EPS excluding extraordinary itemsvalue per share1.91-0.362.17-0.53
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share1.91-0.362.17-0.53